Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HRS9531 in Overweight or Obese Participants
NCT06396429Phase 3Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- May 2024
- Primary completion
- Jul 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HRS9531 in obesity and Overweight (4 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Percentage change from baseline in weight at 48 weeks and Proportion of subjects with weight loss of ≥5% from baseline at 48 weeks. Started May 2024; status: completed.
02
Drugs
HRS9531
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06396429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06396429.